What Is Fixed-Duration CLL Treatment and How Does It Work?
CancerLeukemia

What Is Fixed-Duration CLL Treatment?

What Is Fixed-Duration CLL Treatment?
Carol Yepes/Getty Images
By
Published on July 17, 2026
by
Add us on Google
Not long ago, treatment for chronic lymphocytic leukemia (CLL) often meant needing chemotherapy or a targeted medication for the rest of your life, as long as you tolerated it and your doctor could see that it was successfully controlling the cancer.

Today, those are not your only options. Thanks to newer targeted therapies, some people can have treatment for a set period, known as fixed-duration CLL treatment.

While it’s changing the conversation around CLL management, fixed-duration treatment isn’t appropriate for everyone, and even when you have finished a course of fixed-duration treatment, the CLL is still not cured. CLL essentially requires lifelong treatment regardless. To help you have a more informed conversation with your care team, here’s what to know about fixed-duration CLL therapy.

What Is Fixed-Duration CLL Treatment?

Fixed-duration CLL treatment has a planned start and stop date.

 “You take your medication for a set amount of time, complete the course, and then stop,” says Tibor Kovacsovics, MD, a hematology-oncologist, the chief of hematology, and the medical director of leukemia at City of Hope Cancer Center Phoenix in Goodyear, Arizona.
When the treatment works as intended, it controls the leukemia effectively, often inducing remission. This means that few or no signs suggest that the cancer is active, Dr. Kovacsovics explains. At that point, you transition from active treatment to regular monitoring.

This differs from continuous treatment, in which you take a medication every day with no planned stopping point.

 Continuous treatment goes on for as long as it’s controlling the leukemia and you’re tolerating it well.

Although fixed-duration treatment has a planned end date, the timeline varies by regimen. Most people take these medications for one to two years, says Tara M. Graff, DO, a hematology-oncologist and the director of clinical research for Mission Cancer + Blood, part of University of Iowa Health Care in Des Moines.

At the end of therapy, doctors typically test for minimal residual disease (MRD) using highly sensitive tests to detect very small numbers of leukemia cells that may still be present after treatment.

 If those tests detect leukemia cells, even when labs and imaging look normal, Dr. Graff says your care team may have a conversation about whether continuing one of the medications makes sense before stopping entirely.
Even so, many factors may influence whether this approach is appropriate for you and likely to give you the best outcome, including your CLL genetic biomarkers and other health conditions.

 Treatment recommendations are based on those factors, along with your goals and preferences.

Benefits of Fixed-Duration CLL Treatment

If it’s appropriate for you, fixed-duration treatment for CLL offers several potential benefits.

Defines a Planned End to Treatment

This is one of the most appealing advantages of fixed-duration treatment for many people.

Simply knowing that treatment is designed to end and that you likely won’t need to take cancer medication indefinitely can provide a sense of relief and peace of mind, says John M. Burke, MD, a board-certified hematologist and the medical oncologist at Rocky Mountain Cancer Centers in Aurora, Colorado.

May Provide Relief From Ongoing Side Effects

Fixed-duration treatment limits how long you’ll have exposure to the medications and their potential side effects.

“It also means you spend less time on medications that can weaken the immune system, specifically the B lymphocytes that produce infection-fighting antibodies,” Graff says. This can help your immune system get on with doing its job: protecting you from illness, injury, and infection.

And once the treatment is complete, many side effects you would have experienced long-term on continuous treatment usually improve or go away, Dr. Burke says.

Can Help Reduce Long-Term Costs

In addition to reducing out-of-pocket prescription costs, fixed-duration therapy may also reduce the long-term costs associated with your care.

If treatment-related side effects improve after therapy ends, you may need fewer medications, appointments, or other types of care to manage them.

Might Provide More Future Treatment Options

Cancer cells can become resistant to treatment over time, causing a medication that once worked well to become less effective.

 By limiting how long someone has exposure to a drug, fixed-duration treatment may limit cancer cells’ opportunities to develop that resistance, Kovacsovics says. If the cancer returns, that could mean having more options available, including the possibility of using the same medications again.

Research in this area is still evolving, but it’s worth discussing this potential advantage with your care team.

What to Know Before Starting Fixed-Duration Treatment

As you consider the benefits of fixed‑duration CLL treatment, deciding whether it’s the right approach for you involves the following factors.

The Biology of Your CLL

Your care team will consider your overall health and the specific biology of your CLL before recommending an approach, Kovacsovics says.

Biomarkers are substances, such as certain genes or proteins, that provide information about a cancer.

 Certain CLL biomarkers, such as a tumor protein 53 (TP53) mutation or a chromosomal change called deletion 17p or del(17p) or unmutated IGHV, can influence treatment choices.

 For people who have CLL with these higher-risk biomarkers, fixed-duration therapies may not work as well as continuous treatment.

Closer Monitoring at the Start of Treatment

Currently approved fixed-duration CLL regimens include the medication venetoclax (Venclexta).

 This drug requires a gradual dose increase, called a ramp-up, over several weeks to reduce the risk of tumor lysis syndrome, a serious complication that can occur when cancer cells break down rapidly and release harmful substances into the bloodstream.

Because tumor lysis syndrome can cause kidney failure, your care team generally pays close attention to how well your kidneys are working before you start and closely monitors your kidney health throughout this period.

 You may need more frequent clinic visits, blood tests, and extra hydration during this time. Some people might also need to stay in the hospital to start treatment safely.

Your Lifestyle Priorities

Your priorities are also an important part of the decision. “I approach this as a discussion with the patient and their family about what is important to the patient, including quality of life, lifestyle, and other medical issues,” Graff says.

Think about what makes the most sense for your lifestyle. Some people like the idea of a set treatment end date. For them, it’s worth the initial intensive monitoring of fixed-duration therapy. Others may feel reassured by a lifelong course of a medication that’s actively helping to control the cancer.

Share your priorities with your healthcare team as you weigh up your treatment options.

How Fixed-Duration Therapy Works

Fixed-duration treatment typically combines various medications that attack leukemia cells in different ways. The treatment aims to reduce the number of cancer cells as much as possible, sometimes to levels undetectable by highly sensitive testing. Then, you can potentially stop treatment as long as remission lasts, says Kovacsovics.

Stopping treatment after a fixed period may not mean it’s any less effective than continuous treatment for CLL. A large study found that, over around three years, fixed-duration therapy using venetoclax-based combinations controlled CLL just as effectively as continuous targeted therapy in people with previously untreated CLL.

While the field is developing, cancer specialists currently recommend two fixed-duration regimens for CLL.

BCL-2 Inhibitors + Monoclonal Antibodies

The most common fixed-duration regimen for people receiving their first CLL treatment combines the targeted medication venetoclax (Venclexta) with the monoclonal antibody obinutuzumab (Gazyva), Kovacsovics says.This treatment combination typically lasts 12 months.

 The U.S. Food and Drug Administration (FDA) approved it in May 2019.

Venetoclax blocks B-cell lymphoma 2 (BCL-2), a protein that helps CLL cells stay alive. Without that protein, the leukemia cells die.

 People take venetoclax as a daily pill for the full year.

Obinutuzumab attaches to a protein called CD20 on the surface of CLL cells, helping your immune system to recognize and destroy the cancer cells.

 Doctors administer obinutuzumab by infusion through a vein, known as intravenous (IV) infusion, during the first six months only.

If CLL comes back after treatment, your cancer care team may combine venetoclax with another monoclonal antibody called rituximab (Rituxan) instead of obinutuzumab, says Kovacsovics. Rituximab works similarly to obinutuzumab by binding to CD20 on CLL cells and helping the immune system destroy them.

 This regimen typically lasts 24 months, with healthcare professionals administering rituximab by IV during the first six months and the individual taking venetoclax daily throughout the planned course of treatment.

Next-Gen Doublets (BCL-2 + BTK Inhibitors)

Another fixed-duration option combines venetoclax with acalabrutinib (Calquence), a Bruton tyrosine kinase (BTK) inhibitor, says Burke.

Acalabrutinib blocks BTK, a protein that helps cancer cells grow.

 Together with venetoclax, which targets BCL-2, these drugs attack the disease through different mechanisms. You’d take both medications by mouth.

 Treatment runs for 14 months, with acalabrutinib taken twice daily, and venetoclax added in the third month.

The FDA approved this combination treatment in February 2026 for people with previously untreated CLL whose CLL cells don’t have del(17p) or a TP53 mutation.

 The approval was based on results from a clinical trial involving 867 people showing that those who received acalabrutinib plus venetoclax were no less likely to be alive with their CLL under control at three years compared with those who received long-term chemotherapy.

Researchers continue to study new fixed-duration combinations and different ways to use existing medications to treat CLL.

 That work could lead to even more treatment options in the years ahead.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Typical Treatment of Chronic Lymphocytic Leukemia (CLL). American Cancer Society. February 20, 2026.
  2. Youngblood Gregory S. Chronic Lymphocytic Leukemia (CLL): Understanding the Difference Between Fixed Duration and Continuous Treatment. Mayo Clinic. March 28, 2025.
  3. Al-Sawaf O et al. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. October 28, 2021.
  4. Al-Sawaf O et al. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. The New England Journal of Medicine. December 6, 2025.
  5. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version. National Cancer Institute. April 25, 2025.
  6. Fisher A et al. The Evolving Use of Measurable Residual Disease in Chronic Lymphocytic Leukemia Clinical Trials. Frontiers in Oncology. February 21, 2023.
  7. Allan JN. Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. Advances in Therapy. February 2, 2026.
  8. Chatterjee A et al. ost-Effectiveness of a 12-Month Fixed-Duration Venetoclax Treatment in Combination With Obinutuzumab in First-Line, Unfit Chronic Lymphocytic Leukemia in the United States. Journal of Managed Care & Specialty Pharmacy. October 29, 2021.
  9. Bennett R et al. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions. Clinical Lymphoma, Myeloma & Leukemia. November 2022.
  10. Koffman B. Continuous versus Limited Duration CLL Therapy. CLL Society. April 23, 2026.
  11. Biomarker Testing for Cancer Treatment. National Cancer Institute. December 14, 2021.
  12. VENCLEXTA- venetoclax kit VENCLEXTA- venetoclax tablet, film coated. DailyMed. May 20, 2026.
  13. Anderson MA et al. Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care. Cancers. February 28, 2024.
  14. Durfee EM. Tumor Lysis Syndrome. Critical Care Nurse. June 1, 2022.
  15. Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia. National Cancer Institute. June 17, 2019.
  16. Venetoclax Tablets. Cleveland Clinic.
  17. Obinutuzumab (Intravenous Route). Mayo Clinic. May 1, 2026.
  18. Rituximab Injection. Cleveland Clinic.
  19. Acalabrutinib (Oral Route). Mayo Clinic. June 1, 2026.
  20. FDA Approves Acalabrutinib With Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. U.S. Food & Drug Administration. February 20, 2026.
  21. CALQUENCE- acalabrutinib tablet, film coated. DailyMed. February 19, 2026.
  22. Brown JR et al. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. The New England Journal of Medicine. February 5, 2025.
  23. Wierda WG et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. April 2024.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network

Tawee Tanvetyanon, MD, MPH

Medical Reviewer

Tawee Tanvetyanon, MD, MPH, is a professor of oncologic sciences and senior member at H. Lee Moffitt Cancer Center and Morsani College of Medicine at the University of South Florid...

See full bio
Maggie-Aime-bio

Maggie Aime, MSN, RN

Author

Maggie Aime is a registered nurse with over 25 years of healthcare experience, who brings medical topics to life through informative and inspiring content. Her extensive nursing ba...

See full bio
See Our Editorial PolicyMeet Our Health Expert Network